Novavax (NVAX) Total Non-Current Liabilities (2010 - 2026)

Novavax's Total Non-Current Liabilities history runs 17 years deep, the most recent figure standing at $994.7 million for Q1 2026.

• On a quarterly basis, Total Non-Current Liabilities fell 5.71% year-over-year to $994.7 million in Q1 2026; TTM through Mar 2026 was $994.7 million, a 5.71% decrease from a year earlier, with the FY2025 full-year figure at $1.1 billion, down 41.62% from the prior year.
• Total Non-Current Liabilities retreated to $994.7 million in Q1 2026 per NVAX's latest filing, from $1.1 billion in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $3.0 billion in Q2 2022 and bottomed at $994.7 million in Q1 2026.
• The 5-year median for Total Non-Current Liabilities is $1.9 billion (2024), against an average of $2.0 billion.
• Across the five-year window, Total Non-Current Liabilities jumped 74.64% in 2022 and tumbled 47.19% in 2025, its largest moves.
• Year by year, Total Non-Current Liabilities stood at $2.8 billion in 2022, then dropped by 12.54% to $2.5 billion in 2023, then declined by 26.46% to $1.8 billion in 2024, then tumbled by 41.62% to $1.1 billion in 2025, then dropped by 6.62% to $994.7 million in 2026.
• Per Business Quant, the three latest NVAX Total Non-Current Liabilities figures stand at $994.7 million (Q1 2026), $1.1 billion (Q4 2025), and $1.1 billion (Q3 2025).